Long Noncoding RNAs as Biomarkers in Cancer.
Bolha L, Ravnik-Glavač M, Glavač D. · 2017
Read Long Noncoding RNAs as Biomarkers in Cancer. by Bolha L, Ravnik-Glavač M, Glavač D. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5467329.txt.
Introduction
Bolha, Ravnik-Glavač, and Glavač review long noncoding RNAs as markers for detecting and forecasting cancer. Their review appeared in Disease Markers. These RNAs do not code for proteins. They still regulate key cell processes. They help control gene activity, transport inside cells, and chromosome shape. When their levels go wrong, cancer can develop and progress. That link makes them promising signs of disease.
The review focuses on markers found in body fluids. Tumor tissue biopsies are the classic test, but they are invasive. RNAs circulating in blood and other fluids can be sampled far more gently. The authors survey studies that measured these RNAs in cancer patients. They weigh how well the profiles separate patients from healthy people. They also weigh links to patient outcomes. The authors see strong potential for routine clinical use once the tests are standardized.
Catalog record
| CREATOR | Bolha L, Ravnik-Glavač M, Glavač D. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Long Noncoding RNAs as Biomarkers in Cancer By Luka Bolha, Metka Ravnik-Glavač, Damjan Glavač Published in: Disease Markers DOI: 10.1155/2017/7243968 ABSTRACT Abstract Long noncoding RNAs (lncRNAs) are a relatively well-characterized class of noncoding RNA (ncRNA) molecules, involved in the regulation of various cell processes, including transcription, intracellular trafficking, and chromosome remodeling. Their deregulation has been associated with the development and progression of various cancer types, the fact which makes them suitable as biomarkers for cancer diagnosis and prognosis. In recent years, detection of cancer-associated lncRNAs in body fluids of cancer patients has proven itself as an especially valuable method to effectively diagnose cancer. Cancer diagnosis and prognosis employing circulating lncRNAs are preferential when compared to classical biopsies of tumor tissues, especially due to their noninvasiveness, and have great potential for routine usage in clinical practice. Thus, this review focuses on summarizing the perspectives of lncRNAs as biomarkers in cancer, based on evaluating their expression profiles determined in body fluids of cancer patients. 1. INTRODUCTION Long noncoding RNAs (lncRNAs) belong to a larger group of noncoding RNAs (ncRNAs) and are generally classified as 200 nt–100 kb long transcripts, lacking the open-reading frame [1, 2]. They are usually transcribed by RNA polymerase II and controlled by the transcriptional activators of the SWI/SNF complex. Most of the generated lncRNA transcripts are usually spliced, capped, and polyadenylated in a similar manner as mRNA molecules [3]. lncRNAs represent a large (>80%) and a very heterogeneous group of ncRNAs, with their expression depending largely on the tissue and cellular context [4–7]. Following the discovery of H19 and XIST lncRNAs in 1990s [8, 9], lncRNA per se was initially regarded as a transcriptional noise with practically no or very little function [10]. However, after being identified as a class of RNA molecules in 2002 [11], studies that followed revealed lncRNA importance and indispensability in various cellular processes, including transcription, intracellular trafficking, and chromosome remodeling [3, 12]. In addition, lncRNAs functioning as regulatory factors have been determined for several complex cellular processes, such as cell death, growth, differentiation, identity establishment; controlling apoptosis, epigenetic regulation, genomic imprinting, alternative splicing, regulation of gene expression at posttranscriptional level, chromatin modification, inflammatory pathologies, and, when deregulated, also in various cancer types [13–23]. lncRNAs can be present in practically all cell compartments [24]. However, many lncRNAs with high abundance were identified especially in the nucleus and cytoplasm [25, 26]. lncRNA secondary structures, such as stem loops and hairpins, results of posttranscriptional modifications, enable their interaction with proteins and chromatin and are crucial for lncRNA's vast set of functions [12]. Some of the main mechanisms of action that allow lncRNAs to have a crucial role in various cellular processes [27] are presented in Figure 1. In general, lncRNAs may act as scaffolds for grouping protein complexes (Figure 1(b)), guides to recruit proteins (Figure 1(c)), transcriptional enhancers by bending chromatin (Figure 1(d)), decoys to release proteins from chromatin (Figure 1(a)), or antagonists for other regulatory ncRNAs, for example, microRNAs (miRNAs) [12, 28]. [Figure: Different mechanisms of long noncoding RNA (lncRNA) action. (a) The lncRNAs can act as decoys, titrating away DNA-binding proteins (e.g., transcription factors); (b) lncRNAs may act as scaffolds to bring two or more proteins to spatial proximity or into a complex; (c) lncRNAs may act as guides to recruit proteins to DNA (e.g., chromatin modification enzymes); (d) lncRNA guidance can also be exerted through chromosome looping in an enhancer-like model in cis. lncRNA (red); DNA (black); section of DNA loop (yellow); DNA-binding proteins (blue and light blue). The figure is adapted from John L. Rinn and Howard Y. Chang [12].] Regardless of the whole human genome analyses that enabled better understanding of lncRNA expression, function, and distribution in the human genome, classification of lncRNAs remains to be unified [25, 29]. lncRNAs can be sorted according to their structure, sequence, function, localization, metabolism, and interaction with protein-coding genes or other DNA elements [29]. Recently, Wang et al. classified different types of lncRNAs according to their genomic location and context, exerted effect on DNA sequences, mechanism of functioning, and targeting mechanism [30]. In addition, lncRNAs can be classified into several categories including sense lncRNAs, antisense lncRNAs, bidirectional lncRNAs, intronic lncRNAs, intergenic lncRNAs, promoter-associated lncRNAs, and untranslated region- (UTR-) associated lncRNAs [25, 26]. Nevertheless, current classification methods remain inadequate and relatively nontransparent. The general long-term goal is to develop a unified, systematic, and comprehensive lncRNA classification and annotation framework, utilizing global system biology and genomics-driven approaches. Also, the development of improved tools is required for the integration of complex data from multiple types of experiments into this framework, revealing associations between coding and noncoding transcripts. Such lncRNA classification would be a prerequisite for an improved overview and more effective access and usage of large-scale lncRNA data in various fields and applications [29]. Association of lncRNAs in carcinogenesis was observed due to their differential expression in tumors when compared to normal tissues [31]. lncRNAs H19, MALAT1, and PCA3 are highly expressed tumor-associated lncRNAs that were characterized before the availability of next generation sequencing technologies [32–34]. It has been demonstrated that tumorigenesis mostly results from ectopic lncRNA expression [35]. lncRNAs regulate several oncogenes and tumor suppressor genes at transcriptional and posttranscriptional levels, affecting proliferation, apoptosis, angiogenesis, invasion, migration, and metastasis of tumor cells [36–39]. Also, lncRNA-mediated regulation of chromatin remodeling is essential for the integrity of nuclear structure [23]. In recent years, next-generation and high-throughput sequencing techniques have enabled a significant breakthrough in lncRNA identification and characterization. This resulted in continuously rising amounts of data elucidating deregulated lncRNAs associated with the development of various cancer types [40–42]. In this review, we primarily focus on describing circulating lncRNAs present in different body fluids which represent a promising category of biomarkers for cancer diagnosis, prognosis, and also treatment. 2. LNCRNA-MEDIATED EPIGENETIC MODIFICATIONS Cancer development and progression can be mediated through multiple mechanisms involving lncRNAs [36, 43–46]. In particular, involvement of lncRNAs has been extensively studied in cancer progression, mainly through epigenetic regulation, activation of oncogenic pathways, and crosstalk with other RNA subtypes [29, 47, 48]. As mentioned before, lncRNAs can interact with chromatin remodeling complexes which usually leads to modifications in the expression of target genes, in either cis or trans [49]. In these processes, lncRNAs usually recruit chromatin modification factors, for example, DNA methyltransferase enzymes [50], resulting in gene expression variations often inherited within cell lineages [51]. One of the first reported and characterized lncRNA involved in cancer progression through genome-wide epigenetic reprogramming was HOTAIR [52–54]. HOTAIR acts through interaction with polycomb repressive complex 2 (PRC2) subunits, a key chromatin remodeling complex involved in gene silencing [55]. When deregulated, HOTAIR recruits PRC2 subunits in promoter regions of tumor suppressor genes which results in their transcriptional repression and chromatin condensation, thus, favoring tumor progression. Studies have shown that beside HOTAIR, ANRIL, and XIST, lncRNAs also recruit PRC2 in a similar fashion [52, 56, 57]. Studies have shown that over 200 lncRNAs participate in imprinting processes where, depending on their parental origins, specific expression of nearby lncRNAs promotes suppression of neighboring genes in cis [58, 59]. Here, instead of acting through, for example, PRC2, lncRNAs recruit DNA methyltransferases directly to modify chromatin conformation and DNA methylation. Among many lncRNAs with